NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球阿達木單抗市場:到2027年行業趨勢和預測

Global Adalimumab Market - Industry Trends and Forecast to 2027

出版商 Data Bridge Market Research Private Limited 商品編碼 977591
出版日期 內容資訊 英文 357 Pages
商品交期: 3-5個工作天內
價格
全球阿達木單抗市場:到2027年行業趨勢和預測 Global Adalimumab Market - Industry Trends and Forecast to 2027
出版日期: 2020年11月01日內容資訊: 英文 357 Pages
簡介

在2020年至2027年的預測期內,阿達木單抗的全球市場預計將以4.8%的複合年增長率增長。這份新的市場報告包括以2019年為基準年的2020-2027年的2018年業績和預測數據。

該報告通過適應症,類型,有效成分含量,藥物類型,給藥途徑,人群類型,最終用戶,分銷渠道,國家/地區來調查全球阿達木單抗市場以及市場概況。它提供了公司進入市場的不同趨勢和概況。

目錄

第1章簡介

第2章市場細分

第3章執行摘要

  • 管道分析

第4章全球阿達木單抗市場監管框架

第5章流行病學

第6章阿達木單抗處方

第7章全球Adalimumab市場:贖回方案

  • 美國的兌換方案
  • 中國的贖回情景
  • 日本的贖回情景
  • 中歐和東歐的兌換方案
  • 丹麥的兌換方案
  • 愛爾蘭贖回場景

第8章生物仿製藥的影響

第9章市場概述

  • 促進因素
    • 類風濕關節炎的患病率增加
    • 老年人口增加
    • CRO增加
    • 生物仿製藥簡介
    • 新興市場研究
  • 抑製器
    • 高昂的藥品費用
    • 藥物的副作用
    • 引起癌症的藥物
  • 市場機會
    • 產品流水線的存在
    • 市場參與者的戰略舉措
    • 醫療費用飛漲
    • 兌換政策的存在
  • 挑戰
    • 專利損失
    • 替代品的可用性
    • 長期批准程序

第10章COVID-19對醫療保健行業中阿達木單抗的影響

  • 概述
  • 阿達木單抗和COVID-19
  • 對COVID-19價格的影響
  • 對需求的影響
  • 對供應鏈的影響
  • 製造商的戰略決策
  • 結論

第11章通過調整適應全球阿達木單抗市場

  • 概述
  • 類風濕關節炎
  • 滋補性脊柱炎
  • 尋常型慢性牛皮癬
  • 克隆病
  • 潰瘍性結腸炎
  • 銀屑病關節炎
  • 少年特發性關節炎
  • 化膿性汗腺炎
  • 非傳染性中間體
  • 其他

第12章按類型劃分的全球阿達木單抗市場

  • 概述
  • 生物學
  • 生物相似
    • 阿達木單抗-ATTO
    • 阿達木單抗-BWWD
    • 阿達木單抗-ADBM
    • 阿達木單抗-ADAZ
    • 阿達木單抗-FKJP
    • 阿達木單抗-AFZB
    • 其他

第13章全球阿達木單抗市場,按有效成分含量分類

  • 概述
  • 40毫克/0.4毫升
  • 80毫克/0.8毫升
  • 20毫克/0.4毫升
  • 10毫克/0.1毫升
  • 其他

第14章按藥物類型劃分的全球阿達木單抗市場

  • 概述
  • 品牌藥
  • 仿製藥
    • AMJEVITA
    • HYRIMOZ
    • 胡裡奧
    • 其他

第15章全球阿達木單抗市場,按管理途徑

  • 概述
  • 腸胃外
  • 口頭

第16章按人口類型劃分的全球阿達木單抗市場

  • 概述
  • 成人
  • 兒童

第17章最終用戶的全球Adalimumab市場

  • 概述
  • 醫院
  • 專科診所
  • 醫療保健
  • 其他

第18章,按分銷渠道劃分的全球阿達木單抗市場

  • 概述
  • 醫院內藥房
  • 零售藥房
  • 在線藥房
  • 直接出價
  • 其他

第19章按地區分列的全球阿達木單抗市場

  • 概述
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 瑞士
    • 比利時
    • 土耳其
    • 奧地利
    • 挪威
    • 匈牙利
    • 立陶宛
    • 愛爾蘭
    • 波蘭
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 韓國
    • 澳大利亞
    • 印度
    • 新加坡
    • 馬來西亞
    • 泰國
    • 印度尼西亞
    • 菲律賓
    • 越南
    • 其他
  • 南美洲
    • 巴西
    • 阿根廷
    • 秘魯
    • 其他
  • 中東/非洲
    • 沙特阿拉伯
    • 南非
    • 阿拉伯聯合酋長國
    • 以色列
    • 科威特
    • 埃及
    • 其他

第20章全球阿達木單抗市場競爭形勢

  • 企業份額分析:全球
  • 企業份額分析:北美
  • 企業份額分析:歐洲
  • 企業份額分析:亞太地區

第21章:SWOT

第22章公司簡介

  • ABBVIE INC.
  • AMGEN (EUROPE) GMBH (A SUBSIDIARY OF AMGEN INC.)
  • BIOGEN
  • SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF SANDOZ (A DIVISION OF NOVARTIS AG))
  • MYLAN N.V.
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • CELLTRION INC.
  • COHERUS BIOSCIENCES
  • FRESENIUS KABI DEUTSCHLAND GMBH (A SUBSIDIARY OF FRESENIUS KABI AG)
  • HETERO BIOPHARMA LTD.
  • INNOVENT BIOLOGICS, INC.
  • PFIZER INC.
  • RELIANCE LIFE SCIENCES (A SUBSIDIARY OF RELIANCE INDUSTRIES LIMITED)
  • SAMSUNG BIOEPIS (A SUBSIDIARY OF SAMSUNG BIOLOGICS)
  • ZYDUS CADILA

第23章 問卷

第24章 相連報告

目錄

Global adalimumab market is projected to register a CAGR of 4.8% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Adalimumab Market, By Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Parenteral, Oral), Population Type (Adults, Children), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Tenders, Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of global adalimumab market are:

Increasing geriatric population

Introduction to biosimilars

Market Players:

The key market players for global adalimumab market are listed below:

AbbVie Inc.

Amgen (Europe) GmbH (A Subsidiary of Amgen Inc.)

CELLTRION INC.

Samsung Bioepis (a subsidiary of Samsung Biologics)

Biogen

Coherus BioSciences

Innovent Biologics, Inc.

Mylan N.V.

Zydus Cadila

Hetero Biopharma Ltd.

Fresenius Kabi Deutschland GmbH (A Subsidiary of Fresenius Kabi AG)

Sandoz International GmbH (A Subsidiairy of Sandoz (A Division of Novartis AG))

Pfizer Inc.

Boehringer Ingelheim International GmbH

TABLE OF CONTENTS

1 INTRODUCTION 36

  • 1.1 OBJECTIVES OF THE STUDY 36
  • 1.2 MARKET DEFINITION 36
  • 1.3 OVERVIEW OF GLOBAL ADALIMUMAB MARKET 36
  • 1.4 LIMITATIONS 38
  • 1.5 MARKETS COVERED 40

2 MARKET SEGMENTATION 43

  • 2.1 MARKETS COVERED 43
  • 2.2 GEOGRAPHICAL SCOPE 44
  • 2.3 YEARS CONSIDERED FOR THE STUDY 45
  • 2.4 CURRENCY AND PRICING 45
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 46
  • 2.6 MULTIVARIATE MODELLING 49
  • 2.7 INDICATION LIFELINE CURVE 49
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
  • 2.9 DBMR MARKET POSITION GRID 51
  • 2.10 VENDOR SHARE ANALYSIS 52
  • 2.11 SECONDARY SOURCES 53
  • 2.12 ASSUMPTIONS 53

3 EXECUTIVE SUMMARY 54

  • 3.1 PIPELINE ANALYSIS 60

4 REGULATORY FRAMEWORK OF GLOBAL ADALIMUMAB MARKET 61

5 EPIDEMIOLOGY 64

6 ADALIMUMAB PRESCRIPTION 65

7 GLOBAL ADALIMUMAB MARKET: REIMBURSEMENT SCENARIO 66

  • 7.1 REIMBURSEMENT SCENARIO IN THE U.S. 66
  • 7.2 REIMBURSEMENT SCENARIO IN CHINA 66
  • 7.3 REIMBURSEMENT SCENARIO IN JAPAN 66
  • 7.4 REIMBURSEMENT IN CENTRAL AND EASTERN EUROPE 66
  • 7.5 REIMBURSEMENT SCENARIO IN DENMARK 66
  • 7.6 REIMBURSEMENT SCENARIO IN IRELAND 67

8 IMPACT OF BIOSIMILAR 68

9 MARKET OVERVIEW 69

  • 9.1 DRIVERS 71
    • 9.1.1 RISE IN THE PREVALENCE OF RHEUMATOID ARHTRITIS 71
    • 9.1.2 INCREASING GERIATRIC POPULATION 72
    • 9.1.3 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS 72
    • 9.1.4 INTRODUCTION TO BIOSIMILARS 74
    • 9.1.5 EXPLORATION OF EMERGING MARKETS 74
  • 9.2 RESTRAINTS 75
    • 9.2.1 HIGH COSTS OF DRUGS 75
    • 9.2.2 SIDE EFFECTS OF DRUGS 75
    • 9.2.3 CANCER CAUSING DRUGS 76
  • 9.3 OPPORTUNITIES 78
    • 9.3.1 PRESENCE OF PRODUCT PIPELINE 78
    • 9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 78
    • 9.3.3 INCREASING HEALTHCARE EXPENDITURE 79
    • 9.3.4 PRESENCE OF REIMBURSEMENT POLICIES 80
  • 9.4 CHALLENGES 80
    • 9.4.1 LOSS OF PATENTS 80
    • 9.4.2 AVAILABILITY OF ALTERNATIVES 81
    • 9.4.3 LONG APPROVAL PROCEDURE 82

10 COVID-19 IMPACT ON ADALIMUMAB IN HEALTHCARE INDUSTRY 83

  • 10.1 OVERVIEW 83
  • 10.2 ADALIMUMAB AND COVID-19 83
  • 10.3 PRICE IMPACT OF COVID-19 83
  • 10.4 IMPACT ON DEMAND 84
  • 10.5 IMPACT ON SUPPLY CHAIN 84
  • 10.6 STRATEGIC DECISIONS FOR MANUFACTURERS 85
  • 10.7 CONCLUSION 85

11 GLOBAL ADALIMUMAB MARKET, BY INDICATION 86

  • 11.1 OVERVIEW 87
  • 11.2 RHEUMATOID ARTHRITIS 90
  • 11.3 ANKYLOSING SPONDYLITIS 90
  • 11.4 CHRONIC PLAQUE PSORIASIS 91
  • 11.5 CROHN'S DISEASE 93
  • 11.6 ULCERATIVE COLITIS 94
  • 11.7 PSORIATIC ARTHRITIS 94
  • 11.8 JUVENILE IDIOPATHIC ARTHRITIS 95
  • 11.9 HIDRADENITIS SUPPURATIVA 96
  • 11.10 NON-INFECTIOUS INTERMEDIATE 97
  • 11.11 OTHERS 97

12 GLOBAL ADALIMUMAB MARKET, BY TYPE 99

  • 12.1 OVERVIEW 100
  • 12.2 BIOLOGICS 103
  • 12.3 BIOSIMILARS 103
    • 12.3.1 ADALIMUMAB-ATTO 104
    • 12.3.2 ADALIMUMAB-BWWD 104
    • 12.3.3 ADALIMUMAB-ADBM 104
    • 12.3.4 ADALIMUMAB-ADAZ 104
    • 12.3.5 ADALIMUMAB-FKJP 105
    • 12.3.6 ADALIMUMAB-AFZB 105
    • 12.3.7 OTHERS 105

13 GLOBAL ADALIMUMAB MARKET, BY DOSAGE STRENGTH 106

  • 13.1 OVERVIEW 107
  • 13.2 40MG/0.4ML 110
  • 13.3 80MG/0.8ML 110
  • 13.4 20MG/0.4ML 111
  • 13.5 10MG/0.1ML 112
  • 13.6 OTHERS 113

14 GLOBAL ADALIMUMAB MARKET, BY DRUG TYPE 114

  • 14.1 OVERVIEW 115
  • 14.2 BRANDED 118
  • 14.3 GENERICS 118
    • 14.3.1 AMJEVITA 119
    • 14.3.2 HYRIMOZ 119
    • 14.3.3 HULIO 119
    • 14.3.4 OTHERS 119

15 GLOBAL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 120

  • 15.1 OVERVIEW 121
  • 15.2 PARENTERAL 124
  • 15.3 ORAL 124

16 GLOBAL ADALIMUMAB MARKET, BY POPULATION TYPE 126

  • 16.1 OVERVIEW 127
  • 16.2 ADULTS 130
  • 16.3 CHILDREN 130

17 GLOBAL ADALIMUMAB MARKET, BY END USER 132

  • 17.1 OVERVIEW 133
  • 17.2 HOSPITALS 136
  • 17.3 SPECIALTY CLINICS 136
  • 17.4 HOME HEALTHCARE 137
  • 17.5 OTHERS 138

18 GLOBAL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL 139

  • 18.1 OVERVIEW 140
  • 18.2 HOSPITAL PHARMACIES 143
  • 18.3 RETAIL PHARMACIES 143
  • 18.4 ONLINE PHARMACIES 144
  • 18.5 DIRECT TENDER 145
  • 18.6 OTHERS 145

19 GLOBAL ADALIMUMAB MARKET, BY GEOGRAPHY 147

  • 19.1 OVERVIEW 148
  • 19.2 NORTH AMERICA 154
    • 19.2.1 U.S. 162
    • 19.2.2 CANADA 165
    • 19.2.3 MEXICO 168
  • 19.3 EUROPE 171
    • 19.3.1 GERMANY 179
    • 19.3.2 U.K 182
    • 19.3.3 ITALY 185
    • 19.3.4 FRANCE 188
    • 19.3.5 SPAIN 191
    • 19.3.6 NETHERLANDS 194
    • 19.3.7 RUSSIA 197
    • 19.3.8 SWITZERLAND 200
    • 19.3.9 BELGIUM 203
    • 19.3.10 TURKEY 206
    • 19.3.11 AUSTRIA 209
    • 19.3.12 NORWAY 212
    • 19.3.13 HUNGARY 215
    • 19.3.14 LITHUANIA 218
    • 19.3.15 IRELAND 221
    • 19.3.16 POLAND 224
    • 19.3.17 REST OF EUROPE 227
  • 19.4 ASIA- PACIFIC 228
    • 19.4.1 JAPAN 236
    • 19.4.2 CHINA 239
    • 19.4.3 SOUTH KOREA 242
    • 19.4.4 AUSTRALIA 245
    • 19.4.5 INDIA 248
    • 19.4.6 SINGAPORE 251
    • 19.4.7 MALAYSIA 254
    • 19.4.8 THAILAND 257
    • 19.4.9 INDONESIA 260
    • 19.4.10 PHILIPPINES 263
    • 19.4.11 VIETNAM 266
    • 19.4.12 REST OF ASIA-PACIFIC 269
  • 19.5 SOUTH AMERICA 270
    • 19.5.1 BRAZIL 278
    • 19.5.2 ARGENTINA 281
    • 19.5.3 PERU 284
    • 19.5.4 REST OF SOUTH AMERICA 287
  • 19.6 MIDDLE EAST & AFRICA 288
    • 19.6.1 SAUDI ARABIA 296
    • 19.6.2 SOUTH AFRICA 299
    • 19.6.3 UAE 302
    • 19.6.4 ISRAEL 305
    • 19.6.5 KUWAIT 308
    • 19.6.6 EGYPT 311
    • 19.6.7 REST OF MIDDLE EAST & AFRICA 314

20 GLOBAL ADALIMUMAB MARKET: COMPANY LANDSCAPE 315

  • 20.1 COMPANY SHARE ANALYSIS: GLOBAL 315
  • 20.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 316
  • 20.3 COMPANY SHARE ANALYSIS: EUROPE 317
  • 20.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 318

21 SWOT 319

22 COMPANY PROFILES 320

  • 22.1 ABBVIE INC. 320
    • 22.1.1 COMPANY SNAPSHOT 320
    • 22.1.2 REVENUE ANALYSIS 320
    • 22.1.3 COMPANY SHARE ANALYSIS 321
    • 22.1.4 PRODUCT PORTFOLIO 321
    • 22.1.5 RECENT DEVELOPMENTS 321
  • 22.2 AMGEN (EUROPE) GMBH (A SUBSIDIARY OF AMGEN INC.) 323
    • 22.2.1 COMPANY SNAPSHOT 323
    • 22.2.2 REVENUE ANALYSIS 323
    • 22.2.3 COMPANY SHARE ANALYSIS 324
    • 22.2.4 PRODUCT PORTFOLIO 324
    • 22.2.5 RECENT DEVELOPMENTS 324
  • 22.3 BIOGEN 326
    • 22.3.1 COMPANY SNAPSHOT 326
    • 22.3.2 REVENUE ANALYSIS 326
    • 22.3.3 PRODUCT PORTFOLIO 327
    • 22.3.4 RECENT DEVELOPMENTS 327
  • 22.4 SANDOZ INTERNATIONAL GMBH {A SUBSIDIARY OF SANDOZ (A DIVISION OF NOVARTIS AG)} 328
    • 22.4.1 COMPANY SNAPSHOT 328
    • 22.4.2 REVENUE ANALYSIS 328
    • 22.4.3 PRODUCT PORTFOLIO 329
    • 22.4.4 RECENT DEVELOPMENTS 329
  • 22.5 MYLAN N.V. 330
    • 22.5.1 COMPANY SNAPSHOT 330
    • 22.5.2 REVENUE ANALYSIS 330
    • 22.5.3 PRODUCT PORTFOLIO 331
    • 22.5.4 RECENT DEVELOPMENTS 331
  • 22.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 332
    • 22.6.1 COMPANY SNAPSHOT 332
    • 22.6.2 REVENUE ANALYSIS 332
    • 22.6.3 PRODUCT PORTFOLIO 332
    • 22.6.4 RECENT DEVELOPMENTS 333
  • 22.7 CELLTRION INC. 335
    • 22.7.1 COMPANY SNAPSHOT 335
    • 22.7.2 REVENUE ANALYSIS 335
    • 22.7.3 PRODUCT PORTFOLIO 336
    • 22.7.4 RECENT DEVELOPMENTS 336
  • 22.8 COHERUS BIOSCIENCES 337
    • 22.8.1 COMPANY SNAPSHOT 337
    • 22.8.2 PRODUCT PORTFOLIO 337
    • 22.8.3 RECENT DEVELOPMENTS 337
  • 22.9 FRESENIUS KABI DEUTSCHLAND GMBH (A SUBSIDIARY OF FRESENIUS KABI AG) 338
    • 22.9.1 COMPANY SNAPSHOT 338
    • 22.9.2 REVENUE ANALYSIS 338
    • 22.9.3 PRODUCT PORTFOLIO 338
    • 22.9.4 RECENT DEVELOPMENTS 339
  • 22.10 HETERO BIOPHARMA LTD. 341
    • 22.10.1 COMPANY SNAPSHOT 341
    • 22.10.2 PRODUCT PORTFOLIO 341
    • 22.10.3 RECENT DEVELOPMENTS 341
  • 22.11 INNOVENT BIOLOGICS, INC. 343
    • 22.11.1 COMPANY SNAPSHOT 343
    • 22.11.2 REVENUE ANALYSIS 343
    • 22.11.3 PRODUCT PORTFOLIO 344
    • 22.11.4 RECENT DEVELOPMENTS 344
  • 22.12 PFIZER INC. 345
    • 22.12.1 COMPANY SNAPSHOT 345
    • 22.12.2 REVENUE ANALYSIS 345
    • 22.12.3 PRODUCT PORTFOLIO 346
    • 22.12.4 RECENT DEVELOPMENTS 346
  • 22.13 RELIANCE LIFE SCIENCES (A SUBSIDIARY OF RELIANCE INDUSTRIES LIMITED) 347
    • 22.13.1 COMPANY SNAPSHOT 347
    • 22.13.2 REVENUE ANALYSIS 347
    • 22.13.3 PRODUCT PORTFOLIO 348
    • 22.13.4 RECENT DEVELOPMENTS 348
  • 22.14 SAMSUNG BIOEPIS (A SUBSIDIARY OF SAMSUNG BIOLOGICS) 349
    • 22.14.1 COMPANY SNAPSHOT 349
    • 22.14.2 REVENUE ANALYSIS 349
    • 22.14.3 PRODUCT PORTFOLIO 350
    • 22.14.4 RECENT DEVELOPMENTS 350
  • 22.15 ZYDUS CADILA 351
    • 22.15.1 COMPANY SNAPSHOT 351
    • 22.15.2 REVENUE ANALYSIS 351
    • 22.15.3 PRODUCT PORTFOLIO 352
    • 22.15.4 RECENT DEVELOPMENT 352

23 QUESTIONNAIRE 353

24 RELATED REPORTS 357

LIST OF FIGURES

  • FIGURE 1 GLOBAL ADALIMUMAB MARKET: SEGMENTATION 43
  • FIGURE 2 GLOBAL ADALIMUMAB MARKET: DATA TRIANGULATION 46
  • FIGURE 3 GLOBAL ADALIMUMAB MARKET: DROC ANALYSIS 47
  • FIGURE 4 GLOBAL ADALIMUMAB MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 48
  • FIGURE 5 GLOBAL ADALIMUMAB MARKET: COMPANY RESEARCH ANALYSIS 48
  • FIGURE 6 GLOBAL ADALIMUMAB MARKET: MULTIVARIATE MODELLING 49
  • FIGURE 7 GLOBAL ADALIMUMAB MARKET: INTERVIEW DEMOGRAPHICS 50
  • FIGURE 8 GLOBAL ADALIMUMAB MARKET: DBMR MARKET POSITION GRID 51
  • FIGURE 9 GLOBAL ADALIMUMAB MARKET: VENDOR SHARE ANALYSIS 52
  • FIGURE 10 GLOBAL ADALIMUMAB MARKET: SEGMENTATION 56
  • FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS THE HIGHEST GROWING REGION IN GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 57
  • FIGURE 12 RISE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS AND INCREASING GERIATRIC POPULATION IS DRIVING THE GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 58
  • FIGURE 13 RHEUMATOID ARTHRITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ADALIMUMAB MARKET IN 2020 & 2027 58
  • FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 59
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL ADALIMUMAB MARKET 70
  • FIGURE 16 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS) 73
  • FIGURE 17 FUNCTION OF CRO 73
  • FIGURE 18 HEALTHCARE EXPENDITURE IN 2016 AND 2019 79
  • FIGURE 19 GLOBAL ADALIMUMAB MARKET: BY INDICATION, 2019 87
  • FIGURE 20 GLOBAL ADALIMUMAB MARKET: BY INDICATION, 2019-2027 (USD MILLION) 88
  • FIGURE 21 GLOBAL ADALIMUMAB MARKET: BY INDICATION, CAGR (2020-2027) 88
  • FIGURE 22 GLOBAL ADALIMUMAB MARKET: BY INDICATION, LIFELINE CURVE 89
  • FIGURE 23 GLOBAL ADALIMUMAB MARKET: BY TYPE, 2019 100
  • FIGURE 24 GLOBAL ADALIMUMAB MARKET: BY TYPE 2019-2027 (USD MILLION) 101
  • FIGURE 25 GLOBAL ADALIMUMAB MARKET: BY TYPE, CAGR (2020-2027) 101
  • FIGURE 26 GLOBAL ADALIMUMAB MARKET: BY TYPE, LIFELINE CURVE 102
  • FIGURE 27 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, 2019 107
  • FIGURE 28 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH 2019-2027 (USD MILLION) 108
  • FIGURE 29 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, CAGR (2020-2027) 108
  • FIGURE 30 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, LIFELINE CURVE 109
  • FIGURE 31 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, 2019 115
  • FIGURE 32 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE , 2019-2027 (USD MILLION) 116
  • FIGURE 33 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, CAGR (2020-2027) 116
  • FIGURE 34 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, LIFELINE CURVE 117
  • FIGURE 35 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019 121
  • FIGURE 36 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION) 122
  • FIGURE 37 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027) 122
  • FIGURE 38 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 123
  • FIGURE 39 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, 2019 127
  • FIGURE 40 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, 2019-2027 (USD MILLION) 128
  • FIGURE 41 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, CAGR (2020-2027) 128
  • FIGURE 42 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, LIFELINE CURVE 129
  • FIGURE 43 GLOBAL ADALIMUMAB MARKET: BY END USER, 2019 133
  • FIGURE 44 GLOBAL ADALIMUMAB MARKET: BY END USER, 2019-2027 (USD MILLION) 134
  • FIGURE 45 GLOBAL ADALIMUMAB MARKET: BY END USER, CAGR (2020-2027) 134
  • FIGURE 46 GLOBAL ADALIMUMAB MARKET: BY END USER, LIFELINE CURVE 135
  • FIGURE 47 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019 140
  • FIGURE 48 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION) 141
  • FIGURE 49 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 141
  • FIGURE 50 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 142
  • FIGURE 51 GLOBAL ADALIMUMAB MARKET: SNAPSHOT (2019) 149
  • FIGURE 52 GLOBAL ADALIMUMAB MARKET: BY REGION (2019) 151
  • FIGURE 53 GLOBAL ADALIMUMAB MARKET: BY REGION (2020 & 2027) 151
  • FIGURE 54 GLOBAL ADALIMUMAB MARKET: BY REGION (2019 & 2027) 152
  • FIGURE 55 GLOBAL ADALIMUMAB MARKET: BY INDICATION (2020-2027) 152
  • FIGURE 56 NORTH AMERICA ADALIMUMAB MARKET: SNAPSHOT (2019) 154
  • FIGURE 57 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019) 156
  • FIGURE 58 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027) 156
  • FIGURE 59 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027) 157
  • FIGURE 60 NORTH AMERICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027) 157
  • FIGURE 61 EUROPE ADALIMUMAB MARKET: SNAPSHOT (2019) 171
  • FIGURE 62 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2019) 173
  • FIGURE 63 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027) 173
  • FIGURE 64 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027) 174
  • FIGURE 65 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027) 174
  • FIGURE 66 ASIA- PACIFIC ADALIMUMAB MARKET: SNAPSHOT (2019) 228
  • FIGURE 67 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2019) 230
  • FIGURE 68 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027) 230
  • FIGURE 69 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027) 231
  • FIGURE 70 ASIA- PACIFIC ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027) 231
  • FIGURE 71 SOUTH AMERICA ADALIMUMAB MARKET: SNAPSHOT (2019) 270
  • FIGURE 72 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019) 272
  • FIGURE 73 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027) 272
  • FIGURE 74 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027) 273
  • FIGURE 75 SOUTH AMERICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027) 273
  • FIGURE 76 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: SNAPSHOT (2019) 288
  • FIGURE 77 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019) 290
  • FIGURE 78 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027) 290
  • FIGURE 79 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027) 291
  • FIGURE 80 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027) 291
  • FIGURE 81 GLOBAL ADALIMUMAB MARKET: COMPANY SHARE 2019 (%) 315
  • FIGURE 82 NORTH AMERICA ADALIMUMAB MARKET: COMPANY SHARE 2019 (%) 316
  • FIGURE 83 EUROPE ADALIMUMAB MARKET: COMPANY SHARE 2019 (%) 317
  • FIGURE 84 ASIA-PACIFIC ADALIMUMAB MARKET: COMPANY SHARE 2019 (%) 318